Dezamigren

Before you start using this medicine read the package leaflet carefully and complete the Diagnostic test.

Posology and method of administration:

Adults (18-65 years old)
The recommended dose is one tablet containing 12.5 mg of almotriptan. A second dose may be taken if the symptoms reappear within 24 hours. This second dose may be taken provided that there is a minimum interval of two hours between the two doses.
The efficacy of a second dose for the treatment of the same attack when an initial dose is ineffective has not been examined in controlled trials. Therefore, if a patient does not respond to the first dose, a second dose should not be taken for the same attack.
The maximum recommended dose is two doses (two tablets) in 24 hours.

Children and adolescents (under 18 years of age)
There are no data concerning the use of almotriptan in children and adolescents, therefore its use in this age group is not recommended.

Elderly (over 65 years of age)
No dosage adjustment is required in the elderly. The safety and effectiveness of almotriptan in patients older than 65 years has not been systematically evaluated.

Renal Impairment
Dosage adjustment is not required in patients with mild to moderate renal impairment. Patients with severe renal impairment should take no more than one 12.5 mg tablet in a 24 hour period.

Hepatic Impairment
There are no data concerning the use of almotriptan in patients with hepatic impairment.

Each film-coated tablet contains almotriptan 12.5 mg as almotriptan malate (Almotriptani malas).  

Almotriptan should be taken with liquids as early as possible after the onset of migraine-associated headache but it is also effective when taken at a later stage.
The tablets can be taken with or without food.

Acute treatment of the headache phase of migraine attacks with or without aura.

Hypersensitivity to the active substance or to any of the excipients.
As with other 5-HT1B/1D receptor agonists, almotriptan should not be used in patients with a history, symptoms or signs of any of the following conditions:
- ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal’s angina) or
- severe hypertension and uncontrolled mild or moderate hypertension.
- Patients with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA).
- Peripheral vascular disease.
- Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is
contraindicated.
- Patients with severe hepatic impairment.

Aflofarm Farmacja Polska Spółka z o.o.

27483